Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Oct 12;11(10):1544. doi: 10.3390/cancers11101544

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Effect of imatinib (IM) and IPA-3 on cell viability of chronic myeloid leukemia in the blast phase (CML-BP) cell lines. (A) The cells were treated for 24 h with the indicated doses of IM and IPA-3 individually and in combination followed by 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromine (MTT) assay to test cell viability. Each point represents the mean ± standard deviation (SD) (n ≥ 4), * p < 0.05 in comparison with imatinib. (B) Combination index (CI) values with a 95% confidence interval at all effective levels indicate the nature of the interactions (CI = 1 = additivity, CI < 1 = synergy, CI > 1 = antagonism). Fa is the fraction of cells affected by combination treatment.